Weight Loss
Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%
Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry
Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial
HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics
GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand
GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans
CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target
CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide
Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug
Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits
Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study
Eli Lilly, Novo Nordisk, Zepbound, Wegovy, Weight Loss, Obesity Treatment, Head-to-Head Study, SURMOUNT-5
GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial
Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist
UK Health Secretary Warns Against Misuse of GLP-1 Weight Loss Drugs for Aesthetic Purposes
GLP-1 agonists, weight loss drugs, misuse, aesthetic weight loss, UK health secretary, MHRA warnings
AstraZeneca Advances in Obesity Market with ECC5004 Deal and Promising Clinical Data
AstraZeneca, obesity, ECC5004, GLP-1RA, cardiometabolic diseases, weight loss market
Eli Lilly Rekindles Partnership with KeyBioscience to Bolster Obesity Drug Pipeline
Eli Lilly, obesity drugs, KeyBioscience, partnerships, weight loss treatments